Compounds for the treatment of neurodegenerative diseases
View Patent ↗Compounds and their pharmaceutically acceptable salts for treatment of synucleinopathies, such as Parkinson's disease and tauopathies.
1. A compound selected from the group consisting of:
2. A composition comprising the compound of claim 1 and at least one pharmaceutically acceptable excipient.
3. An article of manufacture, comprising packaging material, the compound of claim 1 , or a pharmaceutically acceptable salt thereof, contained within packaging material, which is used for treating the formation, deposition, accumulation, or persistence of tau fibrils and/or aggregates, and a label that indicates that the compound or pharmaceutically acceptable salt thereof is used for treating the formation, deposition, accumulation, or persistence of tau fibrils and/or aggregates.
4. A method of disrupting or inhibiting the formation, deposition, accumulation, or persistence of tau fibrils and/or aggregates, comprising administering to a mammal having a tauopathy a therapeutically effective amount of the compound of claim 1 .
5. The method of claim 4 , where the compound administered is in an amount between 0.1 mg/Kg/day and 1000 mg/Kg/day.
6. The method of claim 4 , where the compound is administered in an amount between 1 mg/Kg/day and 100 mg/Kg/day.
7. The method of claim 4 , where amount of compound administered is in an amount between 10 mg/Kg/day and 100 mg/Kg/day.
8. A method resulting in neuroprotection from a tauopathy in a mammal suffering therefrom comprising the step of administrating a therapeutically effective amount of a compound of claim 1 .
9. A method of treating a tauopathy in a mammal suffering therefrom comprising the step of administrating a therapeutically effective amount of a compound of claim 1 .
10. The method of claim 9 wherein the tauopathy is selected from the group consisting of Alzheimer's disease with neuronal and glial tau deposition, Pick's disease, progressive supranuclear palsy, corticobasal degeneration, familial frontotemporal dementia/Parkinsonism linked to chromosome 17, amyotrophic lateral sclerosis/Parkinsonism-dementia complex, argyrophilic grain dementia, dementia pugilistic, diffuse neurofibrillary tangles with calcification, progressive subcortical gliosis and tangle only dementia.
11. The method of claim 9 , where the compound administered is in an amount between 0.1 mg/Kg/day and 1000 mg/Kg/day.
12. The method of claim 9 , where the compound is administered in an amount between 1 mg/Kg/day and 100 mg/Kg/day.
13. The method of claim 9 , where amount of compound administered is in an amount between 10 mg/Kg/day and 100 mg/Kg/day.